Our Science

GV1001 improves locomotor dificit and tau aggregation in mouse models of PSP.

· GV1001 ameliorates locomotor deficit by reducing tau phosphorylation in the brain of a mouse models of PSP.

GV1001 improves memory deficits and glial dysfunction in mouse models of AD.

· GV1001 improves learning and memory deficits by reducing synaptic loss in the hippocampus of a mouse models of AD. · GV1001 reduces Aβ plaque burden and tau aggregation by promoting microglia phagocytosis.

Parkinson's disease (PD, MPTP model)

The MPTP model is one of the most commonly used neurotoxin models for PD, characterized by a reduction in dopamine metabolites (dopamine, DOPAC and HVA) in the striatum and loss of dopaminergic neurons in the substantia nigra. We are conducting efficacy studies related to the neuroprotective effects on dopaminergic neurons in the MPTP model.

Multiple sclerosis (MS, MOG35 - 55 model)

The MOG35-55 model is an experimental autoimmune encephalomyelitis (EAE) model that is the gold standard animal model for MS. This model best represents relapsing-remitting multiple sclerosis (RRMS), which is the most common type of MS. We are conducting efficacy studies related to demyelination in the MOG35-55 model.

Amyotrophic lateral sclerosis (ALS)

We are conducting a study on the efficacy of improving motor function using representative pathogenic gene mutation models such as SOD1 and C9orf72, which are related to ALS.